Wolverine Stack Dosage: BPC-157 and TB-500, Separately

What is the Wolverine stack?

A pairing with a marketing name: the Wolverine stack is BPC-157 and TB-500 used at the same time. The name describes a habit rather than a product, which is why it survives whether the two peptides arrive in one vial or in two.

Where the word comes from, in the federal record: FDA's July 2026 briefing document on BPC-157 quotes a clinic website saying that BPC-157 "has been called 'wolverine compound' by many due to its intense healing properties". The agency prints it as an observation about how the substance is marketed, and it attaches the word to BPC-157 alone.

The pairing shows up one document over: FDA's TB-500 briefing document footnotes the marketing pages it surveyed for that substance, and the web address of one of them names a wolverine protocol built on BPC-157 and TB-500 together. We are not reproducing the address, because it belongs to a seller. So the pair sits in the regulator's file twice, both times as something being marketed, and neither time as something formulated or tested.

So two namings are in the record and the rest are not: wolverine compound, which FDA's quotation attaches to BPC-157 by itself, and wolverine protocol, which the address in that TB-500 footnote attaches to the pair.

Other spellings circulate: we are printing the two a reader can go and check in a federal document, and the difference between them is a difference in marketing rather than in chemistry.

Why it has no identity of its own: a stack is not a substance. A molecular formula, a CAS number and a pharmacopeial monograph all describe one substance, and a pairing is a decision about two of them rather than a thing in itself. Each half has its own identifiers and its own literature, and those are the only identities in play.

What the literature does with the phrase: searching PubMed on 9 August 2026 for "wolverine stack"[All Fields] returns zero records, and "wolverine"[Title/Abstract] AND ("BPC-157"[Title/Abstract] OR "TB-500"[Title/Abstract]) also returns zero. The name lives entirely in the market it came from.

What is actually in a Wolverine stack vial?

The one place a composition is written down and checkable: FDA's BPC-157 review names five presentations carrying both peptides, four from its survey of what is marketed and one from a case report in its own adverse event file. Three of those five come with a strength written out, and those three are below; the other two are named without one.

Why that document and not a product page: the strengths in the table are quoted from a federal review a reader can open, rather than from a seller's listing, which is the whole reason this page is able to print any composition at all.

Where the first row comes from, because it matters: the only fully split strength in the table reaches the record through a patient. It is the product in the adverse event report set out in what happens to attribution below, which means the one composition this page can work the arithmetic on is also the one composition somebody reported a reaction to.

The naming problem running down the second column: one seven-residue sequence appears there under three different labels. FDA's TB-500 review describes TB-500 as a synthetic fragment of thymosin beta-4 running from amino acids 17 to 23, with an acetyl group on the N-terminal leucine, so the nasal spray's fragment 17-23 is that same sequence written out by position rather than by brand.

The middle row is the one to watch: it names the parent protein and TB 500 together on one product. FDA states in that same document that several websites treat thymosin beta-4 and TB-500 as interchangeable terms and that the two are not the same substance, so a label carrying both names has not settled which of them is in the vial.

What a milligram figure on a two-peptide vial is: a dry mass, and at most two dry masses. It becomes a strength only when someone decides the water, and that decision is never written on the glass.

What nothing here establishes: that any particular vial holds what its label claims, in the ratio it claims. FDA's two reviews each reach the same verdict about their own substance, that it is not well characterized, citing naming conventions that do not follow chemical nomenclature standards and characterization data missing from the public literature.

No certificate settles it either: searching for one on 9 August 2026 returned nothing outside documents hosted by sellers, which this library does not cite. FDA records separately that no certificate of analysis for TB-500 came with its nomination, and that the one it found in the public domain controls neither endotoxin nor impurities and aggregates.

What a certificate could tell a reader anyway: less than its layout implies, which we take apart in how to read a peptide certificate of analysis.

Why there is no Wolverine stack dosage chart here

The direct answer: stack schedules do circulate, and every one we could find traces back to somebody with a vial to sell. A number whose only home is a shop window is a number we cut rather than reprint, so this page carries none of them.

What that costs a reader, said out loud: this page cannot tell you what anyone calls a weekly amount for the pair, how the two are usually split, how many weeks anyone runs them for, or whether the ratio changes at any point. Those answers exist somewhere. None of them can be traced to a document.

The alternative was worse: printing a split and attributing it to a protocol would read as sourced while pointing at nothing anyone could open. That shape is harder to argue with than an unsourced number and easier to believe, which is what makes it the worse of the two.

What would sit underneath any schedule anyway: a narrative review of injectable peptide therapy that evaluates both of these peptides reports that information on indications, dosing, frequency and duration of treatment remains unknown (Mayfield et al., 2026). Take that verdict, which is reached one peptide at a time, and the pairing has less behind it again.

A split that no published study has tested is still a split somebody chose, and a page that prints it without saying who chose it has passed a stranger's guess off as a finding.

What does survive: the arithmetic, which anyone can check line by line. The rest of this page works it through on example volumes of our own, and our general write-up of how one vial ends up with two incompatible charts is in why two dose charts disagree.

The Wolverine stack calculator

Whole-vial arithmetic, not per peptide: four inputs go in, and what comes back is the concentration, the volume and the barrel reading for the vial total. The split between the two peptides is a label claim, and the converter cannot see it.

How does the units math work on a two-peptide vial?

The extra term a pairing adds: a single-peptide vial hides one unwritten input behind the barrel, which is the water. A vial holding two peptides hides two, because the split decides what share of every draw is which molecule.

The worked case, using the one composition the regulator names: the table below takes a 10mg vial labeled 5mg/5mg and runs it across five water volumes. Every figure is ours, the volumes are examples chosen to show the shape of the curve, and no row says any of them is the right one.

The line the table exists to make: at 2mL a single unit carries 0.05mg of material and 0.025mg of each peptide, and at 1mL those become 0.1mg and 0.05mg. The barrel reads the same either way, so one number on the syringe is standing in for two masses that both moved.

Where the second unwritten input bites: the middle row of the composition table above is labeled 10mg with no split at all. Read as a total, each peptide is 5mg. Read as 10mg of each, the vial holds 20mg and every unit carries twice what the table says. Nothing on the barrel, and nothing in the arithmetic, can tell those two vials apart.

And the scale underneath both of them: a unit is 0.01mL on a U-100 barrel and 0.025mL on a U-40, a third input that the water argument never touches and that the printing on the syringe decides on its own, and we take the U-100 and U-40 scales apart on a page of their own.

Four unwritten inputs, then, and the barrel carries none of them: how much water went in, which of the two scales the syringe was printed to, what the glass really held, and how that mass divides between two molecules. A syringe measures volume honestly and knows nothing about any of it. The general version of the last one lives in our note on doing the math on blend vials.

Is the Wolverine stack one vial or two?

Both are sold, and the difference is not cosmetic: two vials means the ratio between the peptides is decided at every injection and can be changed at any of them. One pre-mixed vial means the ratio was decided before the glass was sealed and cannot be changed afterwards at all.

What that does to any draw from a pre-mixed vial: the label split travels with every volume, whatever its size. On a 5mg/5mg vial half a draw is half of both peptides and twice a draw is twice both of them, so there is no way to move one without moving the other by the same factor.

The search term and the market disagree: the word stack describes separate containers, and the products FDA catalogues include pre-mixed ones. A reader searching for a stack can end up holding a blend, at which point the flexibility the word implies is already gone. Our four-peptide worked example of the same trap is the KLOW blend page.

The ratio nobody enforces: the 5mg/5mg split is what a product is sold as. FDA records no applicable United States Pharmacopeia or National Formulary monograph for TB-500, and no European, Japanese or international pharmacopeial monograph for BPC-157. Those are the two components. Neither document describes a specification for the two of them combined, which is unsurprising, since a monograph describes a substance. Every ratio in this section is arithmetic on a label claim rather than on a measurement.

What happens to attribution when two peptides are on board?

The question a stack page owes a reader: not what the pair does in a person, which no study has measured, but what running two peptides at once costs in the ability to tell what happened. The regulator's own file answers that one directly.

What the file holds: FDA searched its Adverse Event Reporting System for BPC-157 through 4 December 2025 and retrieved three reports, all of them associated with injectable BPC-157 (FDA, BPC-157 briefing document, July 2026).

The report that involves both peptides: a 40-year-old woman reported using a product containing BPC-157 and TB-500 under the skin twice daily for joint healing and wound healing support. She developed diffuse hyperpigmentation and gingival darkening after a week, the same reactions reproduced when she used the product again two weeks later, and they stopped when she discontinued peptides entirely.

What FDA concluded, in both directions: the agency judged the events likely due to the product, because they recurred on rechallenge, and then wrote that because the product contained two peptides it is not possible to assess a potential relationship between BPC-157 and the reported events.

The second of the three lands in the same place: a woman of 55 reported nine days of redness and swelling at the injection site, was on a compounded injectable thymosin at the same time, and FDA writes that the concomitant thymosin is what limits any reading of BPC-157's role.

A reaction that returns on rechallenge is the strongest signal a single case report can carry, and running two peptides at once spends it: the event is real and the cause is unassignable.

One more file, one more pair of untraceable cases: FDA searched its human foods complaint system for TB-500 across 1 January 2004 to 10 March 2025 and retrieved two cases about blended TB-500 and BPC-157, noting that those reports did not include safety assessments (FDA, TB-500 briefing document, July 2026).

The caveats belong here too, and they are the agency's own: reporting to that system is voluntary, a report does not establish that the product caused the event, compounders operating under section 503A generally do not report to FDA at all, and FDA states it cannot draw definitive safety conclusions from those data alone.

What's not known yet?

Where the two sit with the regulator: both appear on FDA's list of bulk drug substances nominated but withdrawn, the entries reading BPC-157 and, separately, thymosin beta-4, fragment (LKKTETQ), also known as TB-500. The page carrying that list is current as of 22 April 2026.

What the list says about each, in almost the same words: compounded drugs containing either may pose a risk for immunogenicity by certain routes of administration, with complexities around peptide-related impurities. For BPC-157 the agency records no, or only limited, safety information for the proposed routes; for the TB-500 fragment it records no identified human exposure data at all.

What happened to both on one day: BPC-157 and TB-500, in free base and acetate forms, went before FDA's Pharmacy Compounding Advisory Committee on 23 July 2026 under docket FDA-2025-N-6895. The agency proposed that none of those forms be added to the 503A bulks list.

The committee then voted the other way: the questions put to it, printed in the meeting's own voting document, asked separately whether each free base and each acetate should be placed on the list, and it voted yes. The Associated Press and NBC News, reporting from the meeting that day, give the tally as 8 in favor, 6 against and 1 abstention.

What that recommendation is worth: the committee advises and the agency decides by rulemaking, so a vote is not a decision. As of 9 August 2026 the meeting page publishes an agenda, briefing documents, voting questions and slides, and no minutes, no vote record and no agency determination.

The gaps named by people reviewing the whole class: a 2026 gerontology review lists combination therapy effects among the significant knowledge gaps for this group of peptides, alongside optimal dosing regimens (Mavrych et al., 2026). A 2026 orthopaedic review covering both peptides puts it more bluntly: preclinical work is promising and clinical trials are currently lacking (Rahman et al., 2026).

The stack-shaped holes, specifically:

• No human study has given BPC-157 and TB-500 together. The literature on that exact pair is one rat experiment, and the nearest human record substitutes the parent protein.
• No registered trial of the pair exists. ClinicalTrials.gov returns zero for BPC-157 AND TB-500, checked 9 August 2026.
• No published work tests whether the ratio matters, and the one ratio with numbers attached to it is not the ratio sold.
• No data describe what the two do to each other in solution, sharing a vial, before either reaches anyone.

A pairing does not inherit evidence from its halves, and the one experiment that added them together found nothing the halves did not already do.

What would change our read: a controlled study of the two given together, in people, at a ratio somebody can name a reason for. Until then the useful question is not how to split a Wolverine stack but whether the pairing was ever more than a name.

How this page is sourced

Every figure was read off the document that carries it: the experimental numbers came from the paper's own record and the regulatory ones from FDA's briefing documents and list pages, opened and read rather than lifted from anybody's summary.

The eleven sources: one animal experiment, one human chart review, five 2026 reviews, three regulator records and one entry for the news reporting of the committee vote, each carrying its identifier or its document link. Every figure on this page traces back to one of them or is arithmetic on figures that do.

What we pulled and what came back: all seven PubMed IDs printed below were fetched from the E-utilities API on 9 August 2026, and all five DOIs resolved at CrossRef the same day with metadata matching the journal, volume, issue and pages printed here. Two of those five answered 403 at the publisher's own site, which is a bot wall rather than a dead record, so CrossRef is the authority we used for them. Every FDA link cited here returned HTTP 200 with a browser user agent and redirects followed, as did both news reports.

What this page deliberately does not carry: a weekly amount, a split, a frequency, a cycle length or a storage window for the pair. Figures of that kind exist online and every one we found traces back to somebody selling the product, so they are cut rather than softened into an unnamed attribution.

Where the search was widened, and what that turned up: the narrow query for this pair returns one experiment. Adding the parent protein to it returns a human chart review in which four patients received BPC-157 alongside thymosin beta-4 rather than TB-500. That paper is on this page and in the list below, because a count claim that only holds under its own query is not a count claim.

The bar a citation has to clear before it ships: that standard, and the route a correction to any figure above takes, are both written out on our methodology page.

Last reviewed: 9 August 2026.

1. 1

   Biçer O, Adanir O, Güleryüz Y, Balci EC, Dinçel YM, Yenigün MY, Aydin C, Bayrak BY. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. doi:10.52312/jdrs.2026.2951. PMID 42542926.

2. 2

   U.S. Food and Drug Administration. FDA Briefing Document for BPC-157-related bulk drug substances, Pharmacy Compounding Advisory Committee, 23 to 24 July 2026. Docket FDA-2025-N-6895. Source for the wolverine compound quotation, the catalogued two-peptide product strengths, and the three adverse event reports. Retrieved 9 August 2026, HTTP 200. BPC-157 briefing document, meeting page.

3. 3

   U.S. Food and Drug Administration. FDA Briefing Document for TB-500-related bulk drug substances, Pharmacy Compounding Advisory Committee, 23 to 24 July 2026. Docket FDA-2025-N-6895. Source for the thymosin beta-4 naming statement, the surveyed marketing footnote, the two blended complaint cases, and the conclusion that the criteria weigh against adding either form to the list. Retrieved 9 August 2026, HTTP 200. TB-500 briefing document, introduction and points to consider.

4. 4

   U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2), including the "nominated but withdrawn" list carrying BPC-157 and Thymosin beta-4, fragment (LKKTETQ), also known as TB-500. Content current as of 22 April 2026. Retrieved 9 August 2026, HTTP 200. fda.gov/drugs/human-drug-compounding.

5. 5

   Mavrych V, Shypilova K, Bolgova O. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. Front Aging. 2026;7:1790247. doi:10.3389/fragi.2026.1790247. PMID 42021992.

6. 6

   Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. J Am Acad Orthop Surg Glob Res Rev. 2026;10(1):e25.00236. doi:10.5435/JAAOSGlobal-D-25-00236. PMID 41490200.

7. 7

   Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF, Gamradt SC, Weber AE. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med. 2026;54(1):223-229. doi:10.1177/03635465251357593. PMID 41476424.

8. 8

   Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. Retrospective chart review, no control group. PMID 34324435.

9. 9

   Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. doi:10.1007/s40279-026-02437-0. PMID 41966639.

10. 10

    Mazza G. Peptide Therapies in Thyroid Health: Emerging Applications in Endocrine and Immune Modulation. Integr Med (Encinitas). 2026;25(2):29-37. PMID 42222211.

11. 11

    News reporting of the committee vote, not an FDA record. Perrone M. FDA reviews BPC-157, TB-500 and other peptides favored by RFK Jr. Associated Press, 23 July 2026. apnews.com. NBC News, 23 July 2026, giving the 8 yes, 6 no, 1 abstention tally. nbcnews.com. Both retrieved 9 August 2026, HTTP 200. The voting questions themselves are in the meeting's own questions document, HTTP 200 the same day.